Earlier this year, Texas Heart Institute received Alpha Phi Foundation’s 2017 Heart to Heart Grant. The $100,000 grant will fund research led by Doris Taylor, Ph.D., director of the Regenerative Medicine Research and the Center for Cell and Organ Biotechnology at the Texas Heart Institute, to study cardiac repair in women at the cellular level.
“We’re just really passionate about these projects that have long-term clinical relevancy, as a women-driven organization and being committed to women’s heart health,” said Colleen Sirhal, vice chair of the Alpha Phi Foundation.
The study will explore sex differences in blood, bone marrow and stem cells of patients enrolled in cell therapy clinical trials.
While bone marrow cell therapy has been used to treat cardiovascular disease in clinical trials, very few studies have been conducted to assess the sex differences in efficacy and outcomes. By performing a proteomic analysis of the samples and evaluating the proteins that cells produce and secrete, the results could shed light on unanswered questions related to critical sex-specific differences in cardiovascular disease, potentially leading to improved cell therapies.
“It’s about time that we’re paying attention to sex differences,” Taylor said. “We’re not just small men. The biology is different.”
Heart disease remains the No. 1 cause of death in both men and women in the United States, yet there’s a limited understanding in the scientific community as to why it affects men and women differently. For example, women 45 years old and younger have a higher likelihood than men of dying within a year of their initial heart attack.
In addition, women have a higher risk of developing small vessel disease, in which the walls of tiny vessels within the heart muscle become blocked rather than larger arteries, causing heart-related chest pain. Because the major coronary arteries may look normal, women with small vessel disease can have a heart attack go undiagnosed and untreated.
“We know heart disease happens differently in men and women,” Taylor said. “More young women than men die of heart disease. Why is that? Is there something that happens early? If we only look at these women who are older, are we missing something major? By looking at healthy, normal younger women, we’re going to be able to do comparisons across time, comparisons by disease, and comparisons by sex. I think that’s really exciting.”
Historically, women and minorities have largely been underrepresented in research and clinical trials, especially pertaining to cardiovascular disease.
Dr. Taylor’s colleague at the Texas Heart Institute, Stephanie Coulter, M.D., a cardiologist and the director of the Center for Women’s Heart and Vascular Health at Texas Heart Institute and a recipient of the 2013 Heart to Heart Grant, is actively recruiting younger women to participate in her research registry.
“Since women are typically affected by heart disease a decade or more later than men, age may also have played a role in this underrepresentation,” Coulter said. “Our Women’s Center research is focusing on women age 18 and older to address this very issue.”
Coulter added that trials focusing on prevention in women, such as the Women’s Health Initiative and Women’s Health Study, have, in fact, had clinical impact. However, the percentage of women enrolling in clinical trials continues to be “disproportionate to the prevalence of cardiovascular disease in women, but we are seeing improvements thanks to multiple initiatives in the U.S. that continue to address the issue of women in clinical trials.”
“It’s easy for people to assume that if you study men, it’ll apply to women, but it seems anathema to people to assume that if you study women it might benefit men,” Taylor said. “At the end of the day, when it comes time to look at the data and ask, ‘How does this treatment work in women? How does this treatment work in men?’, oftentimes there aren’t enough women enrolled in the trials to split that out. Statistically, you’d be doing yourself a disservice.”
Taylor has spent nearly two decades studying key contributors to cardiac repair at the cellular level, specifically looking at proteins cells produce and secrete based on gender as a new frontier in cell therapy.
Early on in Taylor’s career, she studied how bone marrow cells behaved based on gender. She extracted cells from male mice and administered them to female mice and vice versa, allowing her to track the Y chromosome. The results showed that only the males treated with female cells improved. This phenomenon raised the question of whether or not the bone marrow cells were the same.
After measuring the bone marrow cells that were present in males and females, Taylor discovered that the cells were inherently different: In the male mice, there were more inflammatory cells, fewer progenitor and stem cells and a different number of immune cells than in the female mice. In addition, when the bone marrow cells were placed in a petri dish, the female cells produced more growth factors responsible for recruiting repair cells after an injury.
Taylor conducted follow-up experiments in which she gave female and male cells to both female and male mice. The results confirmed her hunch: The only cells that were reparative were the female cells.
“It made me realize a critical detail for the first time: Every time we take bone marrow from a different person with the intention of delivering it back to them as a therapy, if we look at the cells present in the marrow, they’d be different,” Taylor said. “Which means, every time we’re doing an autologous cell therapy trial, in which you take bone marrow and deliver it back to an individual, you are giving each person a completely different or unique drug in that trial.”
Through the Heart to Heart grant, the data from Taylor’s research will allow her to build upon her early research on sex differences and, hopefully, identify a way to optimize cell therapy.
“Already cells are as good as some drugs. If we optimize them and choose the right cells for the right patient at the right time, … maybe we’ll hit the home run,” Taylor said.
The three focus areas of our Prostate #CancerMoonshot: - overcoming treatment resistance - exploring #immunotherapy - understanding the tumor environment Learn more: https://t.co/0ZQCm8tMdR #PCSM #endcancer
The @GlasscockSchool's fall course catalog is chock-full of offerings for ever-curious learners, including classes in the humanities and sciences, foreign languages and personal and professional development. https://t.co/A793BrcLfz https://t.co/8a1K8LbHE2
Last Shasta County Navy Veteran who survived Pearl Harbor attack laid to rest https://t.co/lc5ODzbk9l via @JimSchultz_RS
One internal medicine resident looks back at a time where a patient helped him realize the balance of overly identifying with patients and complete detachment. https://t.co/7xsFWEhVc4
Santa Clarita Air Force Veteran Launches Campaign For Web Series To Depict Modern Soldier Life https://t.co/Td0ds3jxue via @KHTSRADIO
Today’s #VeteranOfTheDay is @USArmy Veteran Stanley Nelson. https://t.co/SHml8yEysj
U.S. Department of Veterans AffairsVeteransAffairs
Today’s #VeteranOfTheDay is Army Veteran Stanley Nelson. Stanley served from 1949 to 1952.Stanley, from Otwell, Indiana in Pike County, joined the Army in 1949 and completed training at Fort Knox. He was sent to Japan and in 1950 was assigned to the 8th Engineer Combat Battalion, 1st Calvary in Korea during the Korean War. On February 14, 1951, Stanley was defending the flank of advancing soldiers near Chipyong in modern-day South Korea. He was wounded by small arms fire in the right shoulder, right foot, left leg and left foot. Stanley was left incapacitated and was captured by the enemy.Stanley endured torture and difficult conditions while held prisoner and was left to die. However, American forces discovered him and evacuated him for medical treatment. The lower part of Stanley’s leg was amputated the following month and he recovered at Percy James Army Hospital in Battle Creek, Michigan. He was medically retired on January 31, 1952.Thank you for your service, Stanley!
Thank you @MBThewoodlands for supporting student scholarships at @MDA_UTHGrad! It also is hosting our next House Calls web chat on sports medicine this Thursday, July 19, at 6:30 p.m. CST at https://t.co/N5UU1Jx4pq. Submit a question for our experts by using #UTHealthHouseCalls.
RT @abc13houston: The most common sports injuries are strains and sprains, but do you know when you might need to see a doctor? The experts…
RT @BCMHouston_News: Tune in to @FOX26Houston tomorrow in the 8 am hour to hear @bcmhouston's Dr. El-Serag discuss the recent CDC report on…
#Cancerpain can be related to the disease and treatment. Hear from Dr. Salahadin Abdi on how patients can find relief. #endcancer https://t.co/snFVjDUjNe
RT @HealthyWomen: 10 Sneaky Ways to Get Fruits and Veggies in Your #Diet: https://t.co/wJ9x39147k #health https://t.co/EWktCmct2J
RT @BCMHouston_News: Certain nail products can cause allergic reactions or irritations. @bcmhouston's Dr. Katta shares what to look out for…
@ParrotsMatter @TargetedOnc @michaelwangmd Hi, yes we are. Here's a list of current clinical trials: https://t.co/JgHpaIKBbX. Best wishes to you.
RT @RiceAthletics: To celebrate #WorldEmojiDay, check out our favorite mascot @SammyTheOwl! 🦉👐 https://t.co/ebIKcsu2Z9